IL17A and psoriasis: These two cytokines have synergistic/cooperative effects on one another [49], and clinical trial data for bimekizumab, a biologic with dual IL-17A and IL-17F inhibition, has achieved high rates of Psoriasis Area and Severity Index (PASI)-100 clearance [50].